NCT00436618 2019-10-22Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous TreatmentMayo ClinicPhase 2 Completed277 enrolled 11 charts
NCT00474929 2019-08-20Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaMayo ClinicPhase 1/2 Completed103 enrolled 12 charts
NCT01334502 2017-08-10Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell LymphomaAlliance for Clinical Trials in OncologyPhase 1 Completed26 enrolled
NCT01022996 2016-05-18Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.NovartisPhase 2 Completed57 enrolled 10 charts
NCT00516412 2015-09-29Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaSwiss Cancer InstitutePhase 2 Completed35 enrolled
NCT00352443 2015-03-06S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaSWOG Cancer Research NetworkPhase 1 Completed66 enrolled
NCT00967044 2015-02-26Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory LymphomaM.D. Anderson Cancer CenterPhase 1/2 Completed31 enrolled 6 charts
NCT00962507 2013-02-15Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaCity of Hope Medical CenterPhase 1 Completed11 enrolled